- |||||||||| Zydelig (idelalisib) / Gilead
Enrollment closed, Combination therapy, Immunomodulating: Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia (clinicaltrials.gov) - May 29, 2014 P1, N=224, Active, not recruiting, Trial primary completion date: May 2014 --> Mar 2017 Recruiting --> Active, not recruiting
|